Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AnaptysBio ( (ANAB) ) has shared an announcement.
On September 29, 2025, AnaptysBio announced plans to separate its business into two independent, publicly traded companies by the end of 2026. This strategic move aims to maximize shareholder value by allowing investors to align with each company’s distinct strategic and financial objectives. The separation will create a Royalty Management Company to manage substantial royalties and a Biopharma Company focused on developing and commercializing therapeutics. This decision reflects AnaptysBio’s commitment to unlocking and maximizing value for its stakeholders.
The most recent analyst rating on (ANAB) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.
Spark’s Take on ANAB Stock
According to Spark, TipRanks’ AI Analyst, ANAB is a Neutral.
AnaptysBio’s overall stock score is primarily impacted by its financial instability, with persistent net losses and negative equity being major concerns. Technical analysis shows a lack of strong momentum, and valuation metrics are unattractive due to ongoing losses. These factors collectively contribute to a low overall stock score.
To see Spark’s full report on ANAB stock, click here.
More about AnaptysBio
AnaptysBio is a biopharmaceutical company focused on developing innovative therapeutics for autoimmune and inflammatory diseases, including gastroenterology, rheumatology, and dermatology. The company has a strong capital position with significant biopharma operations and royalty assets, and it is involved in multiple development stage programs such as rosnilimab, ANB033, and ANB101.
Average Trading Volume: 514,331
Technical Sentiment Signal: Buy
Current Market Cap: $660.2M
For a thorough assessment of ANAB stock, go to TipRanks’ Stock Analysis page.